DSpace@İnönü

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab

Basit öğe kaydını göster

dc.contributor.author Ozdemir, O
dc.contributor.author Zengel, B
dc.contributor.author Yildiz, Y
dc.contributor.author Uluc, BO
dc.contributor.author Cabuk, D
dc.contributor.author Ozden, E
dc.contributor.author Salim, DK
dc.contributor.author Paydas, S
dc.contributor.author Demir, A
dc.contributor.author Diker, O
dc.contributor.author Pilanci, KN
dc.contributor.author Sonmez, OU
dc.contributor.author Vatansever, S
dc.contributor.author Dogan, I
dc.contributor.author Gulmez, A
dc.contributor.author Cakar, B
dc.contributor.author Gursoy, P
dc.contributor.author Yildirim, ME
dc.contributor.author Ayhan, M
dc.contributor.author Karadurmus, N
dc.contributor.author Aykan, MB
dc.contributor.author Cevik, GT
dc.contributor.author Sakalar, T
dc.contributor.author Hacibekiroglu, I
dc.contributor.author Gulbagci, BB
dc.contributor.author Dincer, M
dc.contributor.author Garbioglu, DB
dc.contributor.author Kemal, Y
dc.contributor.author Nayir, E
dc.contributor.author Taskaynatan, H
dc.contributor.author Yilmaz, M
dc.contributor.author Avci, O
dc.contributor.author Sari, M
dc.contributor.author Coban, E
dc.contributor.author Atci, MM
dc.contributor.author Esen, SA
dc.contributor.author Telli, TA
dc.contributor.author Karatas, F
dc.contributor.author Inal, A
dc.contributor.author Demir, H
dc.contributor.author Kalkan, NO
dc.contributor.author Yilmaz, C
dc.contributor.author Tasli, F
dc.contributor.author Alacacioglu, A
dc.date.accessioned 2022-10-05T13:18:56Z
dc.date.available 2022-10-05T13:18:56Z
dc.date.issued 2022
dc.identifier.uri http://hdl.handle.net/11616/62660
dc.description.abstract In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
dc.description.abstract C1 [Ozdemir, Ozlem; Yildiz, Yasar; Yilmaz, Cengiz; Alacacioglu, Ahmet] Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey.
dc.description.abstract [Zengel, Baha] Katip Celebi Univ, Ataturk Training & Res Hosp, Bozyaka Training & Res Hosp, Dept Gen Surg, Izmir, Turkey.
dc.description.abstract [Uluc, Basak Oyan; Demir, Atakan; Sonmez, Ozlem Uysal] Acibadem Hosp, Dept Med Oncol, Istanbul, Turkey.
dc.description.abstract [Cabuk, Devrim; Ozden, Ercan] Kocaeli Univ, Dept Med Oncol, Fac Med Hosp, Kocaeli, Turkey.
dc.description.abstract [Salim, Derya Kivrak] Hlth Sci Univ, Dept Med Oncol, Antalya Training & Res Hosp, Antalya, Turkey.
dc.description.abstract [Paydas, Semra] Cukurova Univ, Dept Med Oncol, Fac Med, Adana, Turkey.
dc.description.abstract [Diker, Omer] Near East Univ Hosp, Dept Med Oncol, Nicosia, Cyprus.
dc.description.abstract [Pilanci, Kezban Nur] Mem Bahcelievler Hosp, Dept Med Oncol, Istanbul, Turkey.
dc.description.abstract [Vatansever, Sezai; Dogan, Izzet] Istanbul Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey.
dc.description.abstract [Gulmez, Ahmet] Inonu Univ, Dept Med Oncol, Fac Med, Malatya, Turkey.
dc.description.abstract [Cakar, Burcu; Gursoy, Pinar] Ege Univ, Dept Med Oncol, Fac Med, Izmir, Turkey.
dc.description.abstract [Yildirim, Mahmut Emre; Ayhan, Murat] Kartal Dr Lutfi Kirdar City Hosp, Dept Med Oncol, Istanbul, Turkey.
dc.description.abstract [Karadurmus, Nuri; Aykan, Musa Baris] Hlth Sci Univ, Dept Med Oncol, Gulhane Training & Res Hosp, Ankara, Turkey.
dc.description.abstract [Cevik, Gokcen Tugba] Usak Univ, Dept Med Oncol, Training & Res Hosp, Usak, Turkey.
dc.description.abstract [Sakalar, Teoman] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkey.
dc.description.abstract [Hacibekiroglu, Ilhan; Gulbagci, Burcu Belen] Sakarya Univ, Dept Med Oncol, Training & Res Hosp, Sakarya, Turkey.
dc.description.abstract [Dincer, Murat; Garbioglu, Duygu Bayir] Osmangazi Univ, Dept Med Oncol, Fac Med Hosp, Eskisehir, Turkey.
dc.description.abstract [Kemal, Yasemin] Med Pk Hosp, Dept Med Oncol, Samsun, Turkey.
dc.description.abstract [Nayir, Erdinc] Med Pk Hosp, Dept Med Oncol, Mersin, Turkey.
dc.description.abstract [Taskaynatan, Halil] Private Ege City Hosp, Dept Med Oncol, Izmir, Turkey.
dc.description.abstract [Yilmaz, Mesut] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey.
dc.description.abstract [Avci, Okan] Namik Kemal Univ Hosp, Dept Med Oncol, Tekirdag, Turkey.
dc.description.abstract [Sari, Murat; Coban, Ezgi] Haydarpasa Numune Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey.
dc.description.abstract [Atci, Muhammed Mustafa] Prof Dr Cemil Tascioglu City Hosp, Dept Med Oncol, Istanbul, Turkey.
dc.description.abstract [Esen, Selin Akturk] Ankara City Hosp, Dept Med Oncol, Ankara, Turkey.
dc.description.abstract [Telli, Tugba Akin] Marmara Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey.
dc.description.abstract [Karatas, Fatih] Karabuk Univ, Dept Med Oncol, Fac Med, Karabuk, Turkey.
dc.description.abstract [Inal, Ali] Mersin City Training & Res Hosp, Dept Med Oncol, Mersin, Turkey.
dc.description.abstract [Demir, Hacer] Afyonkarahisar Hlth Sci Univ, Dept Med Oncol, Afyon, Turkey.
dc.description.abstract [Kalkan, Nurhan Onal] Van Yuzuncu Yil Fac Med, Dept Med Oncol, Van, Turkey.
dc.description.abstract [Tasli, Funda] Bozyaka Training & Res Hosp, Dept Pathol, Izmir, Turkey.
dc.source ANTI-CANCER DRUGS
dc.title The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab
dc.title in women with locally advanced, inflammatory, or early-stage human
dc.title epidermal growth factor receptor 2-positive breast cancer: Turkish
dc.title Oncology Group study


Bu öğenin dosyaları:

Dosyalar Boyut Biçim Göster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster